ascopubs.org

Real-world healthcare costs amongst non-small cell lung cancer (NSCLC) patients tested with a host immune classifier (HIC).

Prevalence of STK11, KEAP1, and KRAS mutations/co-mutations and associated clinical outcomes for patients newly diagnosed with metastatic non-small cell lung cancer. This is an ASCO Meeting Abstract ...
The American Journal of Managed Care

Study: Host Immune Classifier Test Predicts ICI Response in Advanced NSCLC

Patients treated with immune checkpoint inhibitors had significantly different survival rates based on the test, regardless of PD ligand 1 classification. A blood-based proteomic test can help ...
Business Wire

Biodesix to Showcase New Data on Patient Immune Profiling from Multiple Studies at World Lung Conference

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple ...
ascopubs.org

Real-world healthcare resource utilization amongst non-small cell lung cancer (NSCLC) patients tested with a host immune classifier (HIC).

Impact of a pathologist-driven molecular testing protocol on veterans with non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not ...